ASCO June 2nd-June 6th

Education Session

Primary Track: Hematologic Malignancies

Broadening Access to Novel Multiple Myeloma Therapeutics: We Must Do Better

Chair: Surbhi Sidana, MD | Stanford University

Oral Abstract Sessions

 

Abstract 7001:

Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.

Gregory Roloff, Rawan Faramand, Ibrahim Aldoss, Noam Kopmar, Marc Schwartz, Simone Dekker, Chenyu Lin, Sean Tracy, Santiago Mercadal Vilchez, Kaitlyn Dykes, Timothy O'Connor, Mohamed Ahmed, Vishal Gupta, Abdullah Ladha, Stephanie Tsai, Jessica Leonard, Ahmed Galal, Ryan Cassaday, Bijal Shah, Lori Muffly

https://meetings.asco.org/abstracts-presentations/219909

Abstract 7008:

Specialty cancer care and survival in AYA ALL: A U.S. multi-state analysis.

Lori Muffly, Kate Miller, Frances Maguire, Qian Li, Helen Parsons, Theresa Keegan

https://meetings.asco.org/abstracts-presentations/219859

Clinical Science Symposiums

 

Abstract LBA106:

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.

Binod Dhakal, Kwee Yong, Simon Harrison, Maria-Victoria Mateos, Philippe Moreau, Niels van de Donk, Surbhi Sidana, Rakesh Popat, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan Schecter, Katherine Li, Enrique Zudaire, Ying Chen, Jane Gilbert, Lida Bubuteishvili-Pacaud, Nitin Patel, Jesús San-Miguel, Hermann Einsele

https://meetings.asco.org/abstracts-presentations/220015

 

Abstract LBA107:

Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma.

Jason Westin, Olalekan Oluwole, Marie Kersten, David Miklos, Miguel-Angel Perales, Armin Ghobadi, Aaron Rapoport, Anna Sureda, Caron Jacobson, Umar Farooq, Tom van Meerten, Matthew Ulrickson, Mahmoud Elsawy, Lori Leslie, Sridhar Chaganti, Michael Dickinson, Yin Yang, Marco Schupp, Christina To, Frederick Locke

https://meetings.asco.org/abstracts-presentations/220014

Posters

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).

Frederick Locke, Lazaros Lekakis, Herbert Eradat, Javier Munoz, Michael Tees, Sven de Vos, Rajneesh Nath, Don Stevens, Shahbaz Malik, Leslie Popplewell, Mehdi Hamadani, Olalekan Oluwole, Miguel-Angel Perales, David Miklos, Paul Fisher, Lovely Goyal, Gregory Kaufman, Kazuharu Kai, Arun Balakumaran, Sattva Neelapu

https://meetings.asco.org/abstracts-presentations/222697

Abstract 7509; Poster Bd #60:

Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).

Caron Jacobson, Michael Hemmer, Zhen-Huan Hu, Matthew Frank, Leslie Popplewell, Nausheen Ahmed, Yi Lin, Timothy Best, Sara Beygi, Harry Miao, Christine Fu, Fang Sun, Hairong Xu, Marcelo Pasquini

https://meetings.asco.org/abstracts-presentations/218280

Abstract 7571; Poster Bd #122:

Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.

Laura Samples, Hossein Sadrzadeh, Matthew Frigault, Caron Jacobson, Mehdi Hamadani, Ashwath Gurumurthi, Paolo Strati, Roni Shouval, Peter Riedell, Saurabh Dahiya, Jean Yared, Michael Jain, Frederick Locke, Lori Leslie, Narendranath Epperla, Monalisa Ghosh, Alan Skarbnik, Brian Hill, Manali Kamdar, Mazyar Shadman

https://meetings.asco.org/abstracts-presentations/220361

Abstract 8012; Poster Bd #4:

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).

Doris Hansen, Krina Patel, Lauren Peres, Mehmet Kocoglu, Leyla Shune, Gary Simmons, Christopher Ferreri, Shebli Atrash, Ricardo Parrondo, Saurabh Chhabra, Patrick Costello, Shonali Midha, Melissa Alsina, Peter Voorhees, Myo Htut, Douglas Sborov, Jack Khouri, Murali Janakiram, Yi Lin, Surbhi Sidana

https://meetings.asco.org/abstracts-presentations/219990

Abstract 8011; Poster Bd #3:

Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

Niels van de Donk, Philippe Moreau, Alfred Garfall, Manisha Bhutani, Albert Oriol, Ajay Nooka, Thomas Martin, Laura Rosiñol, Maria-Victoria Mateos, Nizar Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez-Lopez, Amrita Krishnan, Michel Delforge, Danielle Trancucci, Raluca Verona, Tara Stephenson, Katherine Chastain, Surbhi Sidana

https://meetings.asco.org/abstracts-presentations/220069

Abstract 8011; Poster Bd #5:

Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.

Aimaz Afrough, Hamza Hashmi, Doris Hansen, Surbhi Sidana, Chul Ahn, Danai Dima, Ciara Freeman, Omar Alexis Castaneda Puglianini, Mehmet Kocoglu, Shebli Atrash, Peter Voorhees, Leyla Shune, Gary Simmons, Douglas Sborov, Christopher Ferreri, Charlotte Wagner, Krina Patel, Jack Khouri, Larry Anderson, Jr, Yi Lin

https://meetings.asco.org/abstracts-presentations/220364